Priority Review granted; PDUFA target action date set for January 21, 2027 -- Submission for Accelerated Approval based on dystrophin as a ...
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the ...
A DNA test gift revealed Kyle Bylin had no genetic match to his family, leading to the discovery he and Jeremy Morrison were ...
Investor's Business Daily on MSN
Dyne Therapeutics trades sideways over an FDA hurdle. Is it time to take profits?
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.
Check out the complete Marvel Rivals patch notes for the July 23 update (version 20260723), featuring the new Thebes map, ...
Texas Abortion Clinics Can Sue Over Law, Supreme Court Rules While the law itself remains intact, justices ruled that providers have the right to challenge the law—known as Senate Bill 8— in federal ...
Polygraph tests can supposedly detect when a person is lying. But how can a machine do that, and can we really trust the ...
If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results